12:00 AM
 | 
Jun 02, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Jakafi: Additional Phase III data

Additional data from the open-label, international Phase III RESPONSE trial in 222 patients with PV who are resistant to or intolerant of hydroxyurea showed that 21% of patients receiving twice-daily 10 mg oral ruxolitinib achieved the primary endpoint of a response at week 32, defined as both the absence of phlebotomy and a >=35% reduction in spleen volume, vs. 1% for patients receiving investigators' choice of best available therapy (p<0.0001). Additionally, 91% of patients receiving ruxolitinib maintained their response at week 48. Furthermore, 60% of patients receiving ruxolitinib achieved hematocrit control in the absence of phlebotomy vs. 20% for best available therapy...

Read the full 490 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >